Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TU7710 Phase 1a SAD in Warfarin-Anticoagulated Healthy Volunteers
NCT06025552Phase 1Completed
- Sponsor
- TiumBio Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hemophilia A and hemophilia B (HB) comparing TU7710 with Placebo (2 arms). Primary endpoints: Number and proportion of participants with adverse events, Number of subjects with significant abnormal laboratory values and 3 more. Started Aug 2023; status: completed.
02
Drugs
TU7710
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT06025552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025552.